Medscape11d
Metronomic Capecitabine Plus Aromatase Inhibitor Boosts Survival in HR+ Breast Cancer
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...
ascopubs.org19d
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204 In light of evolving ...
snmjournals.org19d
Preserved Serotonin Transporter Availability in Parkinson Disease Measured with Either
Journal of Nuclear Medicine January 2025, jnumed.124.268233; DOI: https://doi.org/10.2967/jnumed.124.268233 ...
oncnursingnews25d
Tislelizumab Plus Chemotherapy Receives FDA Approval for First-Line Treatment of Advanced Gastric Cancer
The FDA approved tislelizumab plus chemotherapy for the first-line treatment of unresectable or metastatic gastric or GEJ adenocarcinoma. The FDA has approved tislelizumab-jsgr (Tevimbra) for use with ...
Cancer Research1mon
FDA Approval Summary: Capecitabine Labeling Update under Project Renewal
1Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, Maryland. 2Oncology Center of Excellence (OCE), U.S. Food and Drug ...